Loss of heterozygosity for loci on chromosome 17p in human malignant astrocytoma

D. Fults, R. H. Tippets, Gregory Thomas, Y. Nakamura, R. White

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Loss of constitutional heterozygosity for specific chromosomal loci, when found consistently in a particular tumor type, suggests that a recessive oncogene important in the genesis of that tumor may be present within the involved chromosomal loci. DNA markers that detect restriction fragment length polymorphisms are powerful tools that have been used to detect loss of chromosomal loci in a growing number of human malignancies. The human brain tumor astrocytoma is usually malignant and virtually incurable. Two types of malignant astrocytomas are recognized histopathologically: anaplastic astrocytoma and glioblastoma multiforme. We carried out a restriction fragment length polymorphism analysis of tumors from 15 patients with anaplastic astrocytoma and 20 patients with glioblastoma using polymorphic DNA markers for loci on chromosome 17. Loss of constitutional heterozygosity for loci on chromosome 17 was found in both anaplastic astrocytoma and glioblastoma patients with equal frequency (40% of cases). Our mapping data revealed a region of loss on chromosome 17p between physical loci p11.2 and pter that was common to both patient groups. Taken together with the previously reported finding of loss of heterozygosity for loci on chromosome 10 in glioblastoma, these results indicate that tumorigenesis in the astrocyte lineage may involve recessive oncogenes on two different chromosomes.

Original languageEnglish (US)
Pages (from-to)6572-6577
Number of pages6
JournalCancer Research
Volume49
Issue number23
StatePublished - 1989
Externally publishedYes

Fingerprint

Loss of Heterozygosity
Astrocytoma
Glioblastoma
Chromosomes
Chromosomes, Human, Pair 17
Tumor Suppressor Genes
Genetic Markers
Restriction Fragment Length Polymorphisms
Neoplasms
Chromosomes, Human, Pair 10
Brain Neoplasms
Astrocytes
Carcinogenesis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fults, D., Tippets, R. H., Thomas, G., Nakamura, Y., & White, R. (1989). Loss of heterozygosity for loci on chromosome 17p in human malignant astrocytoma. Cancer Research, 49(23), 6572-6577.

Loss of heterozygosity for loci on chromosome 17p in human malignant astrocytoma. / Fults, D.; Tippets, R. H.; Thomas, Gregory; Nakamura, Y.; White, R.

In: Cancer Research, Vol. 49, No. 23, 1989, p. 6572-6577.

Research output: Contribution to journalArticle

Fults, D, Tippets, RH, Thomas, G, Nakamura, Y & White, R 1989, 'Loss of heterozygosity for loci on chromosome 17p in human malignant astrocytoma', Cancer Research, vol. 49, no. 23, pp. 6572-6577.
Fults, D. ; Tippets, R. H. ; Thomas, Gregory ; Nakamura, Y. ; White, R. / Loss of heterozygosity for loci on chromosome 17p in human malignant astrocytoma. In: Cancer Research. 1989 ; Vol. 49, No. 23. pp. 6572-6577.
@article{17d75a2783ce4f60b082de53c7a346a7,
title = "Loss of heterozygosity for loci on chromosome 17p in human malignant astrocytoma",
abstract = "Loss of constitutional heterozygosity for specific chromosomal loci, when found consistently in a particular tumor type, suggests that a recessive oncogene important in the genesis of that tumor may be present within the involved chromosomal loci. DNA markers that detect restriction fragment length polymorphisms are powerful tools that have been used to detect loss of chromosomal loci in a growing number of human malignancies. The human brain tumor astrocytoma is usually malignant and virtually incurable. Two types of malignant astrocytomas are recognized histopathologically: anaplastic astrocytoma and glioblastoma multiforme. We carried out a restriction fragment length polymorphism analysis of tumors from 15 patients with anaplastic astrocytoma and 20 patients with glioblastoma using polymorphic DNA markers for loci on chromosome 17. Loss of constitutional heterozygosity for loci on chromosome 17 was found in both anaplastic astrocytoma and glioblastoma patients with equal frequency (40{\%} of cases). Our mapping data revealed a region of loss on chromosome 17p between physical loci p11.2 and pter that was common to both patient groups. Taken together with the previously reported finding of loss of heterozygosity for loci on chromosome 10 in glioblastoma, these results indicate that tumorigenesis in the astrocyte lineage may involve recessive oncogenes on two different chromosomes.",
author = "D. Fults and Tippets, {R. H.} and Gregory Thomas and Y. Nakamura and R. White",
year = "1989",
language = "English (US)",
volume = "49",
pages = "6572--6577",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - Loss of heterozygosity for loci on chromosome 17p in human malignant astrocytoma

AU - Fults, D.

AU - Tippets, R. H.

AU - Thomas, Gregory

AU - Nakamura, Y.

AU - White, R.

PY - 1989

Y1 - 1989

N2 - Loss of constitutional heterozygosity for specific chromosomal loci, when found consistently in a particular tumor type, suggests that a recessive oncogene important in the genesis of that tumor may be present within the involved chromosomal loci. DNA markers that detect restriction fragment length polymorphisms are powerful tools that have been used to detect loss of chromosomal loci in a growing number of human malignancies. The human brain tumor astrocytoma is usually malignant and virtually incurable. Two types of malignant astrocytomas are recognized histopathologically: anaplastic astrocytoma and glioblastoma multiforme. We carried out a restriction fragment length polymorphism analysis of tumors from 15 patients with anaplastic astrocytoma and 20 patients with glioblastoma using polymorphic DNA markers for loci on chromosome 17. Loss of constitutional heterozygosity for loci on chromosome 17 was found in both anaplastic astrocytoma and glioblastoma patients with equal frequency (40% of cases). Our mapping data revealed a region of loss on chromosome 17p between physical loci p11.2 and pter that was common to both patient groups. Taken together with the previously reported finding of loss of heterozygosity for loci on chromosome 10 in glioblastoma, these results indicate that tumorigenesis in the astrocyte lineage may involve recessive oncogenes on two different chromosomes.

AB - Loss of constitutional heterozygosity for specific chromosomal loci, when found consistently in a particular tumor type, suggests that a recessive oncogene important in the genesis of that tumor may be present within the involved chromosomal loci. DNA markers that detect restriction fragment length polymorphisms are powerful tools that have been used to detect loss of chromosomal loci in a growing number of human malignancies. The human brain tumor astrocytoma is usually malignant and virtually incurable. Two types of malignant astrocytomas are recognized histopathologically: anaplastic astrocytoma and glioblastoma multiforme. We carried out a restriction fragment length polymorphism analysis of tumors from 15 patients with anaplastic astrocytoma and 20 patients with glioblastoma using polymorphic DNA markers for loci on chromosome 17. Loss of constitutional heterozygosity for loci on chromosome 17 was found in both anaplastic astrocytoma and glioblastoma patients with equal frequency (40% of cases). Our mapping data revealed a region of loss on chromosome 17p between physical loci p11.2 and pter that was common to both patient groups. Taken together with the previously reported finding of loss of heterozygosity for loci on chromosome 10 in glioblastoma, these results indicate that tumorigenesis in the astrocyte lineage may involve recessive oncogenes on two different chromosomes.

UR - http://www.scopus.com/inward/record.url?scp=0024388287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024388287&partnerID=8YFLogxK

M3 - Article

C2 - 2573417

AN - SCOPUS:0024388287

VL - 49

SP - 6572

EP - 6577

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 23

ER -